Vor Bio says telitacicept shows sustained efficacy in China Phase 3 study

Vor Bio (VOR) announced that its collaborator, RemeGen Co., presented 48-week open-label extension data from its Phase 3 study in China evaluating telitacicept in patients with gMG. The results will be presented in a late-breaking session on October 29 at 10:50am PT at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting. The Phase 3 trial in China was a randomized, double-blind, placebo-controlled study in patients with AChR-Ab or MuSK-Ab positive gMG. Following the 24-week double-blind period, all patients entered the OLE, with those previously on placebo crossing over to telitacicept 240mg. “The strength and consistency of these results with telitacicept in China mark a major step forward as we look to redefine long-term disease control for patients living with generalized myasthenia gravis. Achieving sustained and meaningful improvements across both treatment and crossover groups sets a new standard of care expectation globally, especially with nearly eighty-seven percent of patients reaching six-point or greater gains in MG-ADL and over seventy-one percent reaching eight-point or greater gains in QMG. With our global Phase 3 trial now enrolling across 14 countries, we are excited to build on this momentum and work toward delivering the same transformative benefits to patients worldwide,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board.